Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

International Investigation of the Gut-Lung Axis in Systemic Sclerosis–Interstitial Lung Disease

Andréasson, Kristofer LU ; Young, Arissa ; Joshi, Swapna ; Labus, Jennifer S. ; Low, Andrea Hsiu Ling ; Smith, Vanessa ; McMahan, Zsuzsanna ; Proudman, Susanna ; Valenzuela, Antonia and Hunter, Phoebe , et al. (2025) In Arthritis Care and Research
Abstract

Objective: Mounting evidence supports an association between the intestinal microbiota and diverse pulmonary pathologies (ie, gut-lung axis). Although intestinal dysbiosis is a feature of systemic sclerosis (SSc), no prior studies have investigated the relationship between intestinal microbiota and SSc-associated interstitial lung disease (ILD) in a multinational cohort. This study aimed to characterize the intestinal microbiota of SSc-ILD and determine whether specific bacterial species and functional pathways are associated with ILD severity. Methods: Patients with SSc with and without ILD from seven SSc Centers across five continents provided a stool sample. Shotgun metagenomic sequencing was performed using the Illumina NovaSeq 6000... (More)

Objective: Mounting evidence supports an association between the intestinal microbiota and diverse pulmonary pathologies (ie, gut-lung axis). Although intestinal dysbiosis is a feature of systemic sclerosis (SSc), no prior studies have investigated the relationship between intestinal microbiota and SSc-associated interstitial lung disease (ILD) in a multinational cohort. This study aimed to characterize the intestinal microbiota of SSc-ILD and determine whether specific bacterial species and functional pathways are associated with ILD severity. Methods: Patients with SSc with and without ILD from seven SSc Centers across five continents provided a stool sample. Shotgun metagenomic sequencing was performed using the Illumina NovaSeq 6000 to characterize microbial composition at the species level. Quantitative image analysis of high-resolution computed tomography scans of the chest was used to measure radiologic extent of ILD (QILD). Multivariate sparse partial least squares analyses were employed to identify a species signature of ILD and to determine whether specific species and functional pathways are associated with QILD. Results: Among 285 participants (mean disease duration of 9.8 years), 62.5% had ILD. In a multivariate analysis of all participants, patients with ILD had a unique microbial signature compared to those without ILD characterized by increased abundance of candidate pathobiont species. In a subgroup of participants with SSc-ILD (n = 103), specific bacterial species and functional pathways were associated with QILD. Conclusion: This multicenter study demonstrates that distinct intestinal bacterial species are linked to the presence and radiologic extent of ILD in SSc. These species and/or their metabolic products may influence ILD pathogenesis and represent novel treatment targets.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
epub
subject
in
Arthritis Care and Research
publisher
John Wiley & Sons Inc.
external identifiers
  • scopus:105024227216
  • pmid:40757465
ISSN
2151-464X
DOI
10.1002/acr.25623
language
English
LU publication?
yes
additional info
Publisher Copyright: © 2025 American College of Rheumatology.
id
b018b2b6-0a00-4d22-8135-b70ef7330c7d
date added to LUP
2026-03-03 10:58:17
date last changed
2026-03-03 10:58:59
@article{b018b2b6-0a00-4d22-8135-b70ef7330c7d,
  abstract     = {{<p>Objective: Mounting evidence supports an association between the intestinal microbiota and diverse pulmonary pathologies (ie, gut-lung axis). Although intestinal dysbiosis is a feature of systemic sclerosis (SSc), no prior studies have investigated the relationship between intestinal microbiota and SSc-associated interstitial lung disease (ILD) in a multinational cohort. This study aimed to characterize the intestinal microbiota of SSc-ILD and determine whether specific bacterial species and functional pathways are associated with ILD severity. Methods: Patients with SSc with and without ILD from seven SSc Centers across five continents provided a stool sample. Shotgun metagenomic sequencing was performed using the Illumina NovaSeq 6000 to characterize microbial composition at the species level. Quantitative image analysis of high-resolution computed tomography scans of the chest was used to measure radiologic extent of ILD (QILD). Multivariate sparse partial least squares analyses were employed to identify a species signature of ILD and to determine whether specific species and functional pathways are associated with QILD. Results: Among 285 participants (mean disease duration of 9.8 years), 62.5% had ILD. In a multivariate analysis of all participants, patients with ILD had a unique microbial signature compared to those without ILD characterized by increased abundance of candidate pathobiont species. In a subgroup of participants with SSc-ILD (n = 103), specific bacterial species and functional pathways were associated with QILD. Conclusion: This multicenter study demonstrates that distinct intestinal bacterial species are linked to the presence and radiologic extent of ILD in SSc. These species and/or their metabolic products may influence ILD pathogenesis and represent novel treatment targets.</p>}},
  author       = {{Andréasson, Kristofer and Young, Arissa and Joshi, Swapna and Labus, Jennifer S. and Low, Andrea Hsiu Ling and Smith, Vanessa and McMahan, Zsuzsanna and Proudman, Susanna and Valenzuela, Antonia and Hunter, Phoebe and Kim, Grace Hyun and Bozovic, Gracijela and Goldin, Jonathan and Aja, Ezinne and Jacobs, Jonathan P. and Volkmann, Elizabeth R.}},
  issn         = {{2151-464X}},
  language     = {{eng}},
  publisher    = {{John Wiley & Sons Inc.}},
  series       = {{Arthritis Care and Research}},
  title        = {{International Investigation of the Gut-Lung Axis in Systemic Sclerosis–Interstitial Lung Disease}},
  url          = {{http://dx.doi.org/10.1002/acr.25623}},
  doi          = {{10.1002/acr.25623}},
  year         = {{2025}},
}